• Pronase E for Ferroptosis Proteomics

  2026-09-02

  Pronase E supports broad, activity-driven protein digestion for complex ferroptosis research samples. This guide adds a decision framework for preserving mechanistic interpretability when studying the CUL3–MTDH axis and related protein changes in TNBC models.

• RESTRICT-seq Maps Epigenetic SCC Resistance

  2026-09-02

  The RESTRICT-seq preprint introduces a time-gated CRISPR screening strategy for separating genes that influence the establishment, maintenance, or treatment response of squamous cell carcinoma resistance. Its central biological finding identifies KAT6A as an important determinant of oncogene-induced senescence and therapeutic response, providing a framework for studying when epigenetic dependencies become actionable.

• 10074-G5: A c-Myc Inhibitor for Translation

  2026-09-01

  A thought-leadership guide to using 10074-G5 as a mechanistic probe of c-Myc/Max signaling, with a translational framework for testing the MYC/TERT/NFκB axis in esophageal adenocarcinoma and broader cancer research.

• Caspase-8 Activity as a Translational Decision Signal

  2026-09-01

  Caspase-8 is more than an executioner of apoptosis: it can connect treatment-induced stress with caspase-3 activation and pyroptotic signaling. This thought-leadership article examines how recent hyperthermia–cisplatin findings reshape experimental strategy, where IETD-dependent activity measurement adds value, and how the Caspase-8 Fluorometric Assay Kit can support mechanism-led decisions in oncology and broader programmed cell death research.

• Hematoxylin and Eosin Staining Kit Guide

  2026-08-31

  The Hematoxylin and Eosin Staining Kit (SKU K1142) provides ready-to-use hematoxylin and eosin solutions for tissue morphology visualization in paraffin-embedded sections, frozen sections, and cytological preparations. It supports research workflows but is not intended for diagnostic, medical, or clinical decision-making.

• DNP-Induced seRNA Drives NPC Metastasis

  2026-08-31

  The 2023 study identifies seRNA-NPCm as a carcinogen-responsive regulatory RNA that promotes nasopharyngeal carcinoma metastasis through an NPM1/c-Myc/NDRG1 axis. By integrating transcriptomic, nascent-transcription, chromatin, functional, and patient-tissue analyses, the work links chemical exposure to super-enhancer activity and metastatic behavior.

• ARCA EGFP mRNA for Reliable Transfection Assays

  2026-08-30

  Learn how ARCA EGFP mRNA, SKU R1001, helps separate transfection and protein-expression variability from true cell-response effects in mammalian assays. This scenario-based guide covers experimental design, handling, optimization, interpretation, and practical product selection.

• Midecamycin In Vitro: Spectrum and Resistance

  2026-08-29

  Harold C. Neu’s 1983 study defined the in vitro spectrum of Midecamycin, an acetoxy-substituted macrolide antibiotic, across clinical bacterial isolates. The results showed useful activity against many streptococci, staphylococci, Haemophilus influenzae, and Listeria, but weaker activity than erythromycin and no meaningful inhibition of erythromycin-resistant isolates or most tested Gram-negative organisms.

• CNQX Workflows for AMPA/Kainate Studies

  2026-08-28

  CNQX is a practical way to separate AMPA/kainate-driven excitation from NMDA and non-glutamatergic mechanisms. This guide translates its receptor pharmacology into cell, slice, and circuit workflows, with special attention to the cardiovascular neuroscience findings that used CNQX as a pathway-dissection control.

• ERADECs Hijack ERAD to Degrade Membrane Proteins

  2026-08-28

  Song et al. establish ERAD-engaging chimeras (ERADECs), a small-molecule platform that redirects the endoplasmic reticulum-associated degradation pathway toward selective destruction of transmembrane proteins. By linking a SYVN1-binding chemical warhead to a PD-L1 ligand, the study achieves sub-nanomolar target degradation and stronger in vivo tumor suppression than a clinically used PD-L1 antibody.

• Hydroxychloroquine Sulfate: Workflow Guide

  2026-08-27

  Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous-compatible tool for studying autophagy pathway modulation and TLR7/9-associated immune responses in autoimmune disease research. It is appropriate for short-term, water-based workflows but should not be selected for protocols requiring DMSO or ethanol solubility or long-term storage of prepared solutions.

• Bacitracin (B1670): Practical Research Guide

  2026-08-27

  Bacitracin (B1670) provides a peptide antibiotic for controlled studies of bacterial growth and cell wall or peptidoglycan synthesis disruption. It is intended for scientific research workflows only and should not be used for diagnostic, clinical, or medical applications.

• Anti-Epileptic Drugs and Human PON1 Inhibition

  2026-08-26

  The reference study examined how five commonly used antiepileptic drugs inhibit purified human serum paraoxonase-1 (hPON1) in vitro. Phenytoin showed weaker inhibition than gabapentin, valproic acid, and primidone but stronger inhibition than levetiracetam, while all tested compounds were classified as noncompetitive inhibitors.

• SU 5402 Workflows for RTK and Neuronal Models

  2026-08-26

  SU 5402 provides a practical way to perturb VEGFR2, FGFR1, and PDGFRβ signaling across phosphorylation, viability, apoptosis, and cell-cycle assays. This guide translates its cancer biology applications into a carefully bounded strategy for studying signaling in human iPSC-derived sensory neurons and HSV-1 latency models.

• Berberine hydrochloride in Gut–Bone Research

  2026-08-25

  Berberine hydrochloride provides a practical entry point for connecting intestinal microbiota, tuft-cell biology, immune balance, and bone-resorption assays. This workflow translates a recent gut–bone study into reproducible preparation, organoid, microbiome, metabolic, and troubleshooting strategies.

8549 records 1/570 page Next 12345 下5页 Last page